Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

BACKGROUND: The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events (irAEs) including colitis. We aimed to estimate...

Descripción completa

Detalles Bibliográficos
Autores principales: Almutairi, Abdulaali R., Slack, Marion, Erstad, Brian L., McBride, Ali, Abraham, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970695/
https://www.ncbi.nlm.nih.gov/pubmed/33796257
http://dx.doi.org/10.1177/2042098621991279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970695/
https://www.ncbi.nlm.nih.gov/pubmed/33796257
http://dx.doi.org/10.1177/2042098621991279

Ejemplares similares